Avantect Pancreatic Cancer Test
Blood-based multi-analyte, multiomic test intended to support earlier pancreatic cancer detection in elevated-risk patients.
- Developer
- ClearNote Health
- Intended use
- Early Detection
- Cancer scope
- Pancreatic cancer
- Specimen
- Peripheral whole blood
- Molecular modality
- DNA methylation, Multi-omics
- Current version
- Enhanced Avantect Pancreatic Cancer Test (2026)
- Evidence context
- 2 structured studies · 6 indexed performance results · 4 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.